Ngenla Side Effects
Generic name: somatrogon
Medically reviewed by Drugs.com. Last updated on Nov 13, 2023.
Note: This document contains side effect information about somatrogon. Some dosage forms listed on this page may not apply to the brand name Ngenla.
Applies to somatrogon: subcutaneous solution.
Serious side effects of Ngenla
Along with its needed effects, somatrogon (the active ingredient contained in Ngenla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking somatrogon:
More common
- Pale skin
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
Less common
- Constipation
- depressed mood
- dry skin and hair
- feeling cold
- hair loss
- hoarseness or husky voice
- muscle cramps and stiffness
- slowed heartbeat
- weight gain
Incidence not known
- Bloating
- blurred vision
- change in ability to see colors, especially blue or yellow
- chest tightness
- chills
- cough
- darkened urine
- darkening of the skin
- decrease amount in urine
- diarrhea
- difficulty swallowing
- dizziness
- dry mouth
- fainting
- fast heartbeat
- flushed, dry skin
- headache
- hives, itching, skin rash
- increased hunger
- increased thirst
- increased urination
- indigestion
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- loss of appetite
- loss of consciousness
- mental depression
- nausea
- noisy, rattling breathing
- pains in the stomach, side, or abdomen, possibly radiating to the back
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- stomachache
- sweating
- swelling of the fingers, hands, feet, or lower legs
- unexplained weight loss
- vomiting
- yellow eyes or skin
Other side effects of Ngenla
Some side effects of somatrogon may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- cough producing mucus
- difficulty in moving
- earache
- joint pain
- muscle pain
- redness or swelling in the ear
- sore throat
- stuffy or runny nose
For Healthcare Professionals
Applies to somatrogon: subcutaneous solution.
General
Adverse reactions occurring in 5% of patients or greater included injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, and oropharyngeal pain.[Ref]
Dermatologic
Common (1% to 10%): Rash generalized
Frequency not reported: Lipoatrophy
Endocrine
Common (1% to 10%): Hypothyroidism
Uncommon (0.1% to 1%): Adrenal insufficiency
Gastrointestinal
Very common (10% or more): Common (1% to 10%): Vomiting, abdominal pain, tonsillitis
Frequency not reported (somatropin): Pancreatitis
Hematologic
Very common (10% or more): Elevated eosinophils, increasing from normal at baseline over 12 months (29%)
Common (1% to 10%): Anemia
Hypersensitivity
Frequency not reported (somatropin): Severe systemic hypersensitivity reactions, including anaphylaxis and angioedema
Immunologic
Very common (10% or more): Anti-drug antibodies (77.1%)
Local
Very common (10% or more): Injection site reactions (up to 42.2%), including injection site pain (39%), injection site swelling/induration/hypertrophy/inflammation (10%)
Common (1% to 10%): Injection site erythema, injection site pruritus, injection site hemorrhage
Metabolic
Common (1% to 10%): Increased blood creatinine phosphokinase
Frequency not reported: New onset type 2 diabetes mellitus, worsened glycemic control, fluid retention
Musculoskeletal
Common (1% to 10%): Arthralgia, pain in extremity
Frequency not reported: Slipped capital femoral epiphysis, progression of scoliosis, myositis
Nervous system
Very common (10% or more): Headache (up to 16.5%)
Frequency not reported (somatropin): Intracranial hypertension (with papilledema, visual changes, headache, nausea, and/or vomiting)
Ocular
Common (1% to 10%): Allergic conjunctivitis
Oncologic
Frequency not reported (somatropin): New and recurrent malignancy (e.g., intracranial tumors, including meningiomas, as secondary neoplasms)
Other
Very common (10% or more): Pyrexia (up to 16.5%)
Common (1% to 10%): Otitis media, ear pain, arthropod bite
Frequency not reported: Increased risk of mortality in patients with acute critical illness, sudden death in pediatric patients with Prader-Willi syndrome, elevated laboratory tests (e.g., phosphorus, alkaline phosphatase, parathyroid hormone)
Respiratory
Very common (10% or more): Nasopharyngitis, including rhinitis, pharyngitis, rhinitis allergic, pharyngitis streptococcal, viral pharyngitis (33%)
Common (1% to 10%): Cough, oropharyngeal pain, bronchitis
More about Ngenla (somatrogon)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: growth hormones
- En español
Patient resources
Professional resources
Related treatment guides
References
1. Product Information. Ngenla (somatrogon). Pfizer U.S. Pharmaceuticals Group. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.